Pfizer Inc. $PFE Shares Sold by GWN Securities Inc.

GWN Securities Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 3.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 241,654 shares of the biopharmaceutical company’s stock after selling 9,147 shares during the period. Pfizer comprises approximately 1.1% of GWN Securities Inc.’s holdings, making the stock its 22nd biggest position. GWN Securities Inc.’s holdings in Pfizer were worth $5,868,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PFE. Capital Advisors Inc. OK raised its position in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after purchasing an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp bought a new position in Pfizer during the 1st quarter worth $8,283,000. Westbourne Investments Inc. bought a new position in Pfizer during the 1st quarter worth $2,411,000. Bourne Lent Asset Management Inc. grew its stake in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Pfizer during the first quarter valued at $49,968,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Stock Down 0.0%

PFE opened at $24.76 on Tuesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s fifty day moving average is $24.86 and its 200-day moving average is $24.21. The company has a market capitalization of $140.75 billion, a PE ratio of 13.17, a P/E/G ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.